Study of Combivir for Patients With Primary Biliary Cirrhosis
Status:
Completed
Trial end date:
2007-04-01
Target enrollment:
Participant gender:
Summary
This is a proof of principal study to determine whether combination anti-viral therapy with
Combivir impacts on hepatic biochemistry in patients with primary biliary cirrhosis
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
University of Alberta
Collaborators:
Axcan Pharma GlaxoSmithKline
Treatments:
Antiviral Agents Lamivudine, zidovudine drug combination